PARIS — Nine-month results from the BIOFLOW-II trial provide evidence that a biodegradable polymer drug-eluting stent performs similar to a durable polymer DES with regard to in stent late loss and clinical event rates.
Stephan Windecker, MD, researcher with the Bern University Hospital, Switzerland, presented data on the prospective, multicenter, randomized controlled BIOFLOW-II trial. The trial compared the Orsiro sirolimus-eluting stent (Biotronik; n=298), which features a biodegradable polymer, with the Xience Prime everolimus-eluting stent (Abbott; n=154) in 452 patients with a single de novo lesion in up to two coronary arteries; most of the lesions were found in the left anterior descending artery, according to Windecker.
More »